PTEN Deficiency Induces an Extrahepatic Cholangitis-Cholangiocarcinoma Continuum via Aurora kinase A in Mice
The PTEN-AKT pathway is frequently altered in extrahepatic cholangiocarcinoma (eCCA). We aim to evaluate the role of PTEN in the pathogenesis of eCCA and find novel therapies for this disease. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 27, 2024 Category: Gastroenterology Authors: Yan Yang, Jiale Wang, Jianhua Wan, Qianqian Cheng, Zenong Cheng, Xueli Zhou, Oliver Wang, Kelvin Shi, Lingxiang Wang, Bin Wang, Xiaohui Zhu, Jiaxiang Chen, Dongfeng Feng, Yang Liu, Yasmin Jahan-mihan, Ashley N. Haddock, Brandy H. Edenfield, Guang Peng, Je Tags: Research Article Source Type: research
Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease
Liver stiffness measurements (LSM) are recommended for disease prognostication and monitoring. We evaluated if LSM, using transient elastography, and LSM changes predict decompensation and mortality in patients with alcohol-related liver disease (ALD). (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 27, 2024 Category: Gastroenterology Authors: Katrine Holtz Thorhauge, Georg Semmler, Stine Johansen, Katrine Prier Lindvig, Maria Kj ærgaard, Johanne Kragh Hansen, Nikolaj Torp, Camilla Dalby Hansen, Peter Andersen, Benedikt Silvester Hofer, Wenyi Gu, Mads Israelsen, Mattias Mandorfer, Thomas Reibe Tags: Research Article Source Type: research
Multi-omics characterization of healthy and PSC human liver – what we know and what we learn
JK: Deutsche Forschungsgemeinschaft DFG: CRU306, No 42658125. CS: Deutsche Forschungsgemeinschaft DFG: CRU306, No 290522633 and RU5068, No 429191104 and Helmut and Hannelore Greve Foundation, YAEL Foundation. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 27, 2024 Category: Gastroenterology Authors: Jenny Krause, Christoph Schramm Tags: Editorial Source Type: research
Single cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity
In this study we comprehensively interrogate disease-associated cell states (DACS) identified within intra-hepatic tissue and matched PBMCs from either CHB or FC patients, at the resolution of single cells, to provide novel insights into putative mechanisms underlying FC. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 27, 2024 Category: Gastroenterology Authors: Balakrishnan Chakrapani Narmada, Atefeh Khakpoor, Niranjan Shirgaonkar, Sriram Narayanan, Pauline Poh Kim Aw, Malay Singh, Kok Haur Ong, Collins Oduor Owino, Jane Wei Ting Ng, Hui Chuing Yew, Nu Soibah Binte Mohamed Nasir, Veonice Bijin Au, Reina Sng, Niv Tags: Research Article Source Type: research
The Transition from NAFLD to MASLD and Its Impact on Clinical Practice and Outcomes
We read the study by Younossi et al1 with great interest and would like to congratulate the authors for their superb study. Over the last decade, due to changes in lifestyle, there's been a worldwide uptick in metabolic disorders such as obesity and type 2 diabetes, which have directly or indirectly impacted around 37% of the global adult population with non-alcoholic fatty liver disease (NAFLD).2 This condition is also recognized as a leading cause of hepatocellular carcinoma (HCC).3 However, given the insufficient understanding of NAFLD and the potential misconceptions its name may cause, a Delphi conference conducted by...
Source: Journal of Hepatology - February 27, 2024 Category: Gastroenterology Authors: Zhenhua Lu, Weiwei Shao, Jinghai Song Tags: Letter to the Editor Source Type: research
Autoimmune hepatitis: Azathioprine or mycophenolate mofetil for inducing remission?
We read with interest the first randomized-controlled trial evaluating the safety and efficacy of mycophenolate mofetil (MMF) as the first-line over azathioprine (AZA) for induction of adult-onset autoimmune hepatitis (AIH)1 and would like to raise the following points. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 23, 2024 Category: Gastroenterology Authors: Avinash Tiwari, Duncan Khanikar, Santosh Govind Rathod Tags: Letter to the Editor Source Type: research
An in-depth exploration of difference and similarity between NAFLD and MASLD
None. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 23, 2024 Category: Gastroenterology Authors: Yubo Liu, Liao Tan Tags: Letter to the Editor Source Type: research
“Autoimmune Hepatitis: Azathioprine or Mycophenolate Mofetil for inducing remission?”
None for all the above-mentioned authors. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 23, 2024 Category: Gastroenterology Authors: Avinash Tiwari, Duncan Khanikar, Santosh Govind Rathod Tags: Letter to the Editor Source Type: research
Should MMF treatment be the first-line therapy in autoimmune hepatitis?
This study shows that MMF treat ment in naive patients is superior to AZA in terms of both efficacy and tolerability. This study raises a number of questions. Firstly, only 48% of patients in both groups had a compatible but non-typical diagnosis of autoimmune hepatitis. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 23, 2024 Category: Gastroenterology Authors: Laurent Alric Tags: Letter to the Editor Source Type: research
Comment on “Population-based screening works: Effect of integrating screening for hepatitis B and C into the general health check-up in Germany”
We read with great interest the Letter to the Editor by H üppe, Wedemeyer and Cornberg, published in November 2023, reporting on the effect of the newly introduced population-based hepatitis B and C screening in Germany.1 We thank the authors for drawing attention to this topic and strongly support the initiative to scale up screening and testing to ident ify people infected with HBV and HCV. With this letter we want to clarify to what extent surveillance data can be used to interpret the potential effects of the new hepatitis screening approach on HBV and HCV case numbers, as already described. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 22, 2024 Category: Gastroenterology Authors: Renke Biallas, Ruth Zimmermann, Sandra Dudareva Tags: Letter to the Editor Source Type: research
Changing from NAFLD to MASLD: The implications for health-related quality of life data
We agree with the multi-society consensus statement on new fatty liver disease nomenclature to replace non-alcoholic fatty liver disease (NAFLD) with metabolic dysfunction-associated steatotic liver disease (MASLD) using a modified Delphi process led by large pan-national liver associations.1 MASLD is diagnosed as a combination of liver steatosis and the presence of at least one of five cardiometabolic risk factors.1 The new nomenclature and diagnostic criteria are expected to improve awareness and patient identification. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 22, 2024 Category: Gastroenterology Authors: Ryuki Hashida, Dan Nakano, Machiko Kawaguchi, Zobair M. Younossi, Takumi Kawaguchi Tags: Letter to the Editor Source Type: research
CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma
Immune checkpoint inhibitors (ICIs) resistance limits immunotherapy success in hepatocellular carcinoma (HCC). However, the mechanisms underlying immunotherapy resistance remain elusive. We aimed to identify the role of CT10 regulator of kinase-like (CRKL) in HCC against anti-PD-1 therapy. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 22, 2024 Category: Gastroenterology Authors: Peiyi Xie, Mincheng Yu, Bo Zhang, Qiang Yu, Yufei Zhao, Mengyuan Wu, Lei Jin, Jiuliang Yan, Binghai Zhou, Shuang Liu, Xiaoqiang Li, Chenhao Zhou, Xiaodong Zhu, Cheng Huang, Yongfeng Xu, Yongsheng Xiao, Jian Zhou, Jia Fan, Mien-Chie Hung, Qinghai Ye, Lei G Tags: Research Article Source Type: research
Letter: Changing from NAFLD to MASLD: The Implications for health related quality of life data
We agree with the multi-society consensus statement on new fatty liver disease nomenclature to replace non-alcohol fatty liver disease (NAFLD) with metabolic dysfunction-associated steatotic liver disease (MASLD) using a modified Delphi process led by large pan-national liver associations.1 MASLD is diagnosed as a combination of liver steatosis and the presence of at least one of five cardiometabolic risk factors.1 The new nomenclature and diagnostic criteria are expected to improve awareness and patient identification. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 22, 2024 Category: Gastroenterology Authors: Ryuki Hashida, Dan Nakano, Machiko Kawaguchi, Zobair M. Younossi, Takumi Kawaguchi Tags: Letter to the Editor Source Type: research
Reply to: Population-based screening works: Effect of integrating screening for hepatitis B and C into the general health check-up in Germany
Writing manuscript draft: RB; All authors reviewed the manuscript and approved the final version; Coordination: RB. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 22, 2024 Category: Gastroenterology Authors: R. Biallas, R. Zimmermann, S. Dudareva Tags: Letter to the Editor Source Type: research
Potential augmentation of terlipressin antidiuretic effects by gabapentinoids
We read with interest the recent research article by Tonon et al, which characterizes the patterns of decompensation in patients with cirrhosis, with particular focus on the 45% of patients who experience a non-acute decompensation.1 These patients, who invariably decompensate with ascites (80%), are managed as outpatients and the paper highlights the need to prevent their further decompensation. (Source: Journal of Hepatology)
Source: Journal of Hepatology - February 22, 2024 Category: Gastroenterology Authors: Penelope N. Markham, Jasmohan S. Bajaj, Paul J. Thuluvath, David Koch, Joseph Palumbo Tags: Letter to the Editor Source Type: research
